Overview
Mermaid diagram (expand to render)
RedHill Biopharma Ltd. is an Israeli specialty biopharmaceutical company focused on the development and commercialization of drugs for gastrointestinal and infectious diseases, with emerging programs in oncology and central nervous system (CNS) disorders. Founded in 2009 and headquartered in Tel Aviv, Israel, RedHill has established itself as a specialty pharma company with a diverse pipeline targeting unmet medical needs in GI, infectious diseases, and increasingly, neurodegenerative conditions["@redhill"].
The company trades on the NASDAQ under the ticker RDHL and has built its portfolio through a combination of in-house development and strategic acquisitions of late-stage clinical candidates. While RedHill's primary focus has been on gastrointestinal and infectious diseases, the company has progressively expanded its strategic interests to include CNS disorders, particularly those with gastrointestinal components such as Parkinson's disease["@sec"].
Company Overview
| Attribute | Details |
|-----------|---------|
| Headquarters | Tel Aviv, Israel |
| Founded | 2009 |
| Ticker | NASDAQ: RDHL |
| Focus Areas | GI diseases, Infectious diseases, Oncology, CNS |
| Status | Public (clinical-stage) |
| Employees | ~50-100 |
History and Development
RedHill Biopharma was founded in 2009 with a strategic focus on late-stage clinical development of novel therapeutic candidates. The company's business model emphasizes:
Acquisition of Late-Stage Assets: Identifying and acquiring clinical candidates that have demonstrated proof-of-concept in early-to-mid stage trials
Rapid Development Pathways: Accelerating development through regulatory pathways and strategic partnerships
Global Commercialization: Building commercial infrastructure for global distributionKey Milestones
- 2009: Company founded in Israel
- 2013: Movantik (naloxegol) licensing agreement with AstraZeneca
- 2014: Initial public offering on NASDAQ
- 2018: Talicia (RHB-105) FDA approval for H. pylori
- 2018: Aemcolo (RHB-412) FDA approval for travelers' diarrhea
- 2019: Expansion of CNS programs and research initiatives
- 2020-2024: Continued pipeline advancement including upamostat and RHB-107
RedHill's research approach combines expertise in several therapeutic areas:
Gastrointestinal Expertise
The company's foundation in GI drugs provides unique insights into conditions with gut-brain axis involvement:
Barrier Function: Understanding of intestinal permeability and epithelial integrity
Microbiome Modulation: Experience with GI microbiology and bacterial interactions
Local Drug Delivery: MMX (Multi-Matrix) technology for colonic delivery
Transit Disorders: Expertise in motility and constipation therapeuticsCNS Research Interests
RedHill's expansion into CNS has focused on conditions with established or hypothesized gut connections:
Neurodegeneration: Parkinson's disease and Alzheimer's disease
Neuroinflammation: Targeting inflammatory pathways common to GI and CNS
Blood-Brain Barrier: Strategies for CNS drug penetration
Gut-Brain Axis: Leveraging GI expertise for neurological conditionsPipeline and Programs
Approved Products
Movantik/Naloxegol
Movantik (naloxegol) is a peripheral μ-opioid receptor antagonist for the treatment of opioid-induced constipation (OIC)[@movantik].
- Mechanism: Selective antagonist of peripheral μ-opioid receptors in the GI tract, blocking opioid-induced inhibition of intestinal motility without affecting central opioid analgesia
- Indication: Opioid-induced constipation in adults with chronic non-cancer pain
- Status: FDA approved (2014), marketed globally
- Partnership: Licensed to AstraZeneca for global commercialization
The drug represents a first-in-class therapy for OIC and has generated significant commercial revenue. Importantly, the drug's mechanism has relevance to Parkinson's disease research given the documented alterations in opioid signaling in PD patients[@opioids].
Talicia
Talicia (RHB-105) is a fixed-dose combination therapy for the treatment of Helicobacter pylori infection[@talicia].
- Mechanism: Triple-combination therapy including amoxicillin, clarithromycin, and omeprazole
- Indication: Helicobacter pylori infection
- Status: FDA approved (2018) — First approval for a RedHill-developed drug
- Significance: Demonstrated company's ability to advance drugs through regulatory approval
Talicia's success validated RedHill's development model and provided commercial revenue to fund CNS expansion efforts.
Aemcolo
Aemcolo (RHB-412/rifamycin MMX) is a rifamycin-based antibiotic for the treatment of travelers' diarrhea[@aemcolo].
- Mechanism: Broad-spectrum antibiotic with MMX colonic delivery technology
- Indication: Travelers' diarrhea caused by non-invasive strains of E. coli
- Status: FDA approved (2018)
Clinical Pipeline
RHB-107 (Upamostat)
RHB-107 (upamostat) is a serine protease inhibitor with potential applications in oncology and virology.
- Mechanism: Inhibits serine proteases involved in tumor invasion and viral entry
- Indication: Various cancers, potential for viral infections
- Stage: Phase 2 clinical trials
- CNS Potential: Research has explored CNS applications given protease involvement in neuroinflammation
RHB-104
RHB-104 is an oral combination therapy for Mycobacterium avium complex (MAC) infection.
- Mechanism: Combination antibiotic regimen
- Indication: MAC infection, a common opportunistic infection in immunocompromised patients
- Stage: Phase 3 clinical trials
- Neurodegeneration Link: Research has explored connections between mycobacterial infections and neuroinflammation
CNS Pipeline Evolution
RedHill has progressively expanded its CNS interest, particularly in neurodegenerative diseases:
| Program | Stage | Indication | Neurodegeneration Relevance |
|---------|-------|------------|----------------------------|
| RHB-107 (upamostat) | Phase 2 | Various cancers | Protease inhibition in neuroinflammation |
| RHB-104 | Phase 3 | MAC infection | Microbial-neuroinflammation connections |
| CNS-001 | Discovery | Neurodegeneration | Gut-brain axis modulators |
Parkinson's Disease Relevance
RedHill's expertise in gastrointestinal therapeutics positions them uniquely for Parkinson's disease research, given the strong gut-brain axis connections documented in PD pathophysiology[@gutbrainpd][@microbiomepd].
α-Synuclein and the Gut
Research has established compelling connections between gut health and Parkinson's disease:
Braak Hypothesis: The hypothesis that α-synuclein pathology may originate in the enteric nervous system and propagate via the vagus nerve to the CNS[@gutbrainpd]
Lewy Bodies in ENS: Presence of Lewy bodies in the enteric nervous system of PD patients
Early GI Symptoms: Constipation and other GI symptoms often precede motor symptoms by yearsMicrobiome Alterations
PD patients demonstrate distinct microbiome profiles compared to healthy controls[@microbiomepd]:
- Reduced microbial diversity
- Increased pro-inflammatory bacteria
- Decreased anti-inflammatory species
- Metabolite alterations (short-chain fatty acids, etc.)
RedHill's GI expertise positions them to potentially address these pathways:
Barrier Integrity: Products targeting gut epithelial function may reduce systemic inflammation relevant to PD
Microbiome Modulation: Understanding of GI microbiology could translate to PD therapeutic strategies
Anti-inflammatory Effects: GI anti-inflammatory expertise may cross-apply to neuroinflammationOpioid Signaling in PD
Parkinson's disease patients often develop constipation from dopaminergic medications, and opioid signaling is altered in PD:
- Movantik (naloxegol): As a peripheral μ-opioid receptor antagonist, may have utility in PD-associated constipation management
- Opioid Dysregulation: Research has documented altered opioid peptide levels in PD brains
- Pain Management: PD patients often require pain management where opioid antagonists may play a role
Clinical Trial Considerations
PD clinical trials require specific considerations:
| Factor | Relevance | RedHill Capability |
|--------|-----------|-------------------|
| Motor symptoms | UPDRS, MDS-UPDRS, Hoehn & Yahr staging | Clinical trial infrastructure |
| Non-motor symptoms | REM sleep behavior disorder, constipation, depression | GI expertise relevant |
| Biomarkers | α-synuclein PET ligands, DaTscan imaging | Biomarker development capability |
| Disease stage | Early vs. advanced PD | Patient stratification understanding |
| GI complications | Constipation, microbiome | Direct therapeutic relevance |
Alzheimer's Disease Potential
While RedHill's CNS expansion has focused primarily on PD, the company's approach has implications for AD:
Neuroinflammation
Both GI and CNS inflammation share common pathways:
- IL-6 and TNF-α: Pro-inflammatory cytokines elevated in both GI inflammation and AD
- Microglial Activation: Common pathway in neuroinflammation and GI inflammation
- Peripheral-CNS Communication: Inflammatory signals from gut may influence brain inflammation
Blood-Brain Barrier
Strategies for GI drug delivery may inform CNS delivery:
- Barrier Modulation: Understanding of epithelial barriers may translate to BBB strategies
- Transporter Exploitation: Carrier-mediated transport for GI drugs may have CNS analogs
- Nanoparticle Delivery: Experience with GI nanoparticles may inform brain delivery
Competitive Landscape
RedHill operates in a competitive landscape across multiple therapeutic areas:
GI Competition
| Company | Key Products | RedHill Differentiation |
|---------|-------------|------------------------|
| AstraZeneca | Movantik (licensed) | Co-development partner |
| Ferring | Picoprep | Different mechanism |
| Salix | Xifaxan | Similar MMX technology |
Neurodegeneration Competition
| Company | Approach | RedHill Advantage |
|---------|----------|-------------------|
| Biogen/Eisai | Anti-amyloid antibodies | Gut-brain axis expertise |
| Roche | Anti-tau antibodies | Different mechanism |
| Generic dopaminergic | Symptomatic treatment | Novel mechanisms |
Financial Overview
RedHill's financial position reflects its clinical-stage status[@sec]:
- Market Capitalization: $50-150M range (variable based on pipeline news)
- Revenue: Product sales from Movantik, Talicia, and Aemcolo
- Partnerships: Strategic collaborations with AstraZeneca and others
- R&D Investment: Significant investment in clinical development
The company's business model depends on successful clinical development and subsequent commercialization or partnership deals.
Strategic Positioning
RedHill's strategic approach to neurodegeneration leverages several key assets:
Strengths
GI Expertise: Deep understanding of gut physiology and therapeutics
MMX Technology: Proprietary colonic delivery platform
Regulatory Experience: Demonstrated ability to obtain FDA approval
Clinical Infrastructure: Established trial capabilitiesOpportunities
Gut-Brain Axis: Growing research validates this therapeutic approach
PD Population: Large unmet need in Parkinson's disease
Microbiome Modulation: Emerging therapeutic area with GI company fit
Combination Approaches: Potential for GI + CNS combination therapiesChallenges
CNS Development: Limited track record in CNS drug development
Competition: Major pharma dominates neurodegeneration space
Resource Constraints: Clinical-stage company limitations
Regulatory Hurdles: CNS drug development complexityResearch and Development Strategy
RedHill's approach to neurodegeneration R&D includes:
Short-Term (1-2 years)
- In-licensing: Acquire CNS candidates with established proof-of-concept
- Academic Partnerships: Collaborate with PD researchers on gut-brain axis
- Biomarker Development: Validate biomarkers linking GI and CNS endpoints
Medium-Term (2-5 years)
- Clinical Trials: Initiate PD-focused clinical trials
- Indication Expansion: Explore AD and other neurodegenerative conditions
- Combination Therapies: Develop GI + CNS combination approaches
Long-Term (5+ years)
- Platform Development: Build proprietary neurodegeneration platform
- Global Launch: Commercialize neurodegeneration products
- Pipeline Expansion: Diversify CNS pipeline
Collaboration Opportunities
RedHill may pursue various collaboration models:
Academic Collaborations: Partnership with PD research centers
Pharma Partnerships: Out-licensing or co-development with major pharma
Biotech Partnerships: Acquire complementary technologies
Foundation Partnerships: Work with Parkinson's Foundation and similar organizationsFuture Directions
The company's expansion into CNS reflects broader industry recognition of gut-brain connections in neurodegeneration:
- Phase 2initiation: RHB-107 CNS-focused trials
- Pipeline Additions: Acquire additional CNS candidates
- PD Program: Initiate dedicated Parkinson's disease program
- Biomarker Development: Validate predictive biomarkers
See Also
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Gut-Brain Axis in Parkinson's Disease](/mechanisms/gut-brain-axis-parkinsons)
- [Opioid Signaling in Neurodegeneration](/mechanisms/opioid-signaling-neurodegeneration)
- [Microbiome and Neurodegeneration](/mechanisms/microbiome-neurodegeneration)
- [Neuroinflammation in Parkinson's Disease](/mechanisms/neuroinflammation-parkinsons)
External Links
- [RedHill Biopharma Official Website](https://www.redhillbio.com)
- [SEC Filings](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001554463)
- [ClinicalTrials.gov](https://clinicaltrials.gov/)
References
[RedHill Biopharma Official Website](https://www.redhillbio.com)
[SEC Filings](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001554463)
[Webster et al., Long-term safety and efficacy of naloxegol (2016)](https://pubmed.ncbi.nlm.nih.gov/26827025/)
[Malani et al., Talicia for Helicobacter pylori infection (2019)](https://pubmed.ncbi.nlm.nih.gov/31797679/)
[Braak et al., Staging of brain pathology related to sporadic Parkinson's disease (2003)](https://pubmed.ncbi.nlm.nih.gov/12446254/)
[Sampson et al., Gut microbiota regulate motor deficits and neuroinflammation in Parkinson's disease (2016)](https://pubmed.ncbi.nlm.nih.gov/27814545/)
[DuPont et al., Rifamycin MMX for travelers' diarrhea (2019)](https://pubmed.ncbi.nlm.nih.gov/30376194/)
[Jankovic, Parkinson's disease: clinical features and diagnosis (2008)](https://pubmed.ncbi.nlm.nih.gov/18344391/)